Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals Inc (RYTM) today and set a price target of $40. The company’s shares opened today at $27.92.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 7.8% and a 48.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Allogene Therapeutics Inc, and Voyager Therapeutics Inc.
Rhythm Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $41.
See today’s analyst top recommended stocks >>
Based on Rhythm Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.69 million. In comparison, last year the company had a GAAP net loss of $10.62 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RYTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
